An analysis using exposure data from UKB revealed that PCSK9 inhibitor has the potential to significantly increase the risk of patients with PCOS (IVW: OR [95%CI] = 1.7174 [1.3278, 2.1071], p=0.65× 10−2; Weighted model: OR [95%CI] = 1.6286 [1.1780, 2.0792], p=4.36× 10−2). This evidence concerns the gene PCSK9 and polycystic ovary syndrome.